← Back to Search

Rho Kinase Inhibitor

Netarsudil Eye Drops for Fuchs' Dystrophy

Phase < 1
Waitlist Available
Led By Emma Davies, MD
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at post-operative month one visit and then every 2 months for 1 year
Awards & highlights

Summary

This trial will look at whether a certain medication can improve healing time and cell counts after a specific eye surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at post-operative month one visit and then every 2 months for 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at post-operative month one visit and then every 2 months for 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in central corneal pachymetry over time
Change in endothelial cell count over time

Side effects data

From 2021 Phase 2 trial • 40 Patients • NCT04498169
15%
Corneal verticillata
10%
Conjunctival hypaeremia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Once Daily Netarsudil Ophthalmic Solution
Twice Daily Netarsudil Ophthalmic Solution

Trial Design

1Treatment groups
Experimental Treatment
Group I: Netarsudil useExperimental Treatment1 Intervention
Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Netarsudil
FDA approved

Find a Location

Who is running the clinical trial?

Massachusetts Eye and Ear InfirmaryLead Sponsor
107 Previous Clinical Trials
12,961 Total Patients Enrolled
Emma Davies, MDPrincipal InvestigatorMassachusetts Eye and Ear Infirmary
Sila E Bal, MD, MPHPrincipal InvestigatorMassachusetts Eye and Ear Infirmary

Media Library

Netarsudil Ophthalmic (Rho Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04752020 — Phase < 1
Fuchs' Dystrophy Research Study Groups: Netarsudil use
Fuchs' Dystrophy Clinical Trial 2023: Netarsudil Ophthalmic Highlights & Side Effects. Trial Name: NCT04752020 — Phase < 1
Netarsudil Ophthalmic (Rho Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04752020 — Phase < 1
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top